Boston, MA -- (SBWIRE) -- 01/03/2014 -- The acute lymphocytic/lymphoblastic leukemia therapeutics market has growth potential as the incidence rate of the disease is increasing all over the globe. The incidence of acute lymphocytic/lymphoblastic leukemia is higher in children from 0 to 14 years than in those aged 15 years and above. However, acute lymphocytic/lymphoblastic leukemia may also occur in adults. The acute lymphocytic/lymphoblastic leukemia market is segmented into two types-childhood acute lymphocytic/lymphoblastic leukemia and adult acute lymphocytic/lymphoblastic leukemia.

The acute lymphocytic/lymphoblastic leukemia therapeutics market primarily covers regimens and drugs (patented, off-patent, and pipeline). The growing acute lymphocytic/lymphoblastic leukemia population is an impetus for the growth of the market. This market is expected to grow at a CAGR of 4.0% from 2015 to 2020. In 2012, the overall ALL therapeutics market was dominated by Linker regimen, Hyper-CVAD regimen, and Nucleoside metabolic inhibitors treatments. However, by 2020, the overall share of these drugs and regimens will be largely impacted by the launch of Graspa (ERYtechPharma), an innovative form of L-Asparaginase, followed by Marqibo (Talon Therapeutics) and Inotuzumab Ozogamicin (Pfizer, Inc.).

View Full Report Details and Table of Contents

In contrast to the growth of the market, the cost of the therapies is majorly restraining the acute lymphocytic/lymphoblastic leukemia therapeutics market. In addition, patent expirations of some of the existing drugs in the market are also expected to limit the market growth during 2013 to 2020.

Market players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were some of the major strategies adopted by the players from January 2008 to November 2013.

Scope of the report:

This research report categorizes the acute lymphocytic/lymphoblastic leukemia market in G8 countries into the following segments:

Acute Lymphocytic/Lymphoblastic Leukemia Market, by Drug
Existing Regimens/Drugs
Hyper-CVAD Regimen
CALGB 8811 Regimen
Linker Regimen
Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
Oncaspar
Pipeline Drugs (Phase III)
Graspa
Marqibo
Inotuzumab Ozogamicin
Acute Lymphocytic/Lymphoblastic Leukemia Market, by Geography
North America
U.S.
Canada
Europe
Germany
France
Italy
Spain
U.K.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth
- HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth
- Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
- Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants
- Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential
- Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players
- Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth
- Caprolactam Global Market to 2020 - Growth driven by Rising Demand from Nylon Fiber and Resin and Films Applications in China
- Ethylbenzene Global Market to 2020 - Growth in South and Central America to Outpace China, While Asia-Pacific Continues to be the Major Volume Contributor
- Purified Terephthalic Acid Global Market to 2020 - Overcapacity and Declining Margins to Hinder Global Demand in the Short Term